Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan's Ulipristal, Dogged By Liver Concerns, Gets An FDA Rejection

Executive Summary

US FDA issued a complete response letter for ulipristal acetate for the treatment of bleeding in women with uterine fibroids. The action wasn't unanticipated, but a disappointment nonetheless while Allergan tries to sell its women's health unit.

Advertisement

Related Content

Myovant's Relugolix May Be Competitive With AbbVie Drug In Uterine Fibroids
Allergan Endures Another R&D Setback With Rapastinel Failing Three Pivotal Studies
Allergan Thinks It’s Ready To Withstand Restasis Generics
Rovi and Recordati Deemed Top Picks By Analyst
Esmya Review Held Back Gedeon Richter in First Half
Allergan Fights Generic Headwinds, Activist Investors
AbbVie Prices Oral Endometriosis Drug Orilissa In Value Range, Focusing On Access
Keeping Track: Delay (For Celgene), Delay (For Allergan), Goose! (Approval For Lilly)
AbbVie's Got A Competitive Edge With Elagolix For Women With Uterine Fibroids
Allergan Relying On 'Six Stars' And Other R&D Programs To Blunt Restasis Blow

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123730

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel